Biovaxpharma-Inhalosomes - Development of a nonionic surfactant vesicle platform formulation for drug encapsulation and pulmonary delivery

Biovaxpharma-Inhalosomes - 开发用于药物封装和肺部输送的非离子表面活性剂囊泡平台配方

• 批准号: 720199
• 金额: $ 25.06万
• 依托单位: INHALOSOME-C LTD
• 依托单位国家: 英国
• 项目类别: GRD Development of Prototype
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=720199
• 关键词: Biovaxpharma; Inhalosomes; Development; nonionic; surfactant

Inhalosomes are lipid nanoparticles designed to tackle the unmet need for effective treatment of serious pulmonary diseases, such as in cancer, infection and autoimmunity. Current systemic treatments are only partially effective as they are a blanket approach where low levels of drug reach the lung. Inhalosome vesicles will be develop as a platform drug encapsulating technology that can be aerosolized for lung delivery to provide significant improvements in therapy. The initial intention is to demonstrate the feasibility of Inhalosomes for the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC). With this project, the Inhalosome prototype will be manufactured to cGMP and the stability of the formulation tested Using the manufactured Inhalosome preparation, subsequent studies will evaluate the Inhalosome-cisplatin for toxicology and in Phase I and II studies to demonstrate safety and efficacy in man for treating NSCLC. Expectations are that the Cisplatin-Inhalosome combination will significantly increase the effectiveness of NSCLC chemotherapy treatment, increasing the survival rate and extend life expectancy and will improve the patient experience.

吸入体是脂质纳米粒子，旨在解决有效治疗严重肺部疾病（例如癌症、感染和自身免疫性疾病）方面尚未满足的需求。目前的全身治疗仅部分有效，因为它们是一种笼统方法，低水平的药物到达肺部。吸入体囊泡将被开发为一种平台药物封装技术，可以雾化用于肺部输送，从而显着改善治疗效果。最初的目的是证明 Inhalosomes 治疗肺癌，特别是非小细胞肺癌（NSCLC）的可行性。通过该项目，Inhalosome 原型将按照 cGMP 生产，并测试制剂的稳定性。后续研究将评估 Inhalosome-顺铂的毒理学，并在 I 期和 II 期研究中证明其对人体的安全性和有效性。治疗非小细胞肺癌。预计顺铂-Inhalosome 组合将显着提高 NSCLC 化疗的有效性，提高生存率并延长预期寿命，并改善患者体验。